Q32 Bio Inc.
The research page contains a warning that has not been mapped to a supported model interpretation. The company research remains available, but the complete score is withheld until the warning is reviewed.
QTTB · Price history
Price at last available close
$8.71
−$0.52 (-5.63%) 1M
2026-10-27
Tap or drag sideways to inspect a price. Use two fingers to compare automatically. Release to scroll. Use Shift + arrow keys to compare with a keyboard.
Company & revenue
About Q32 Bio Inc.
Primary reporting period: 2025-12-31 · Research updated Oct 12, 2026. A research update is not a new financial filing.
Who they are
Operating as a clinical-stage biotechnology firm, Q32 Bio Inc. is dedicated to developing biologic therapies aimed at re-establishing healthy immune equilibrium in patients across the United States suffering from autoimmune and inflammatory disorders stemming from dysfunctional immune responses. The company's primary investigational therapy, ADX-097, is a humanized anti-C3d monoclonal antibody fusion protein designed to normalize complement regulation. This candidate has successfully finished its Phase I clinical trial, targeting severe renal and other complement-driven conditions where patient needs are largely unmet, such as lupus nephritis, IgA nephropathy, C3 glomerulopathy, and ANCA-associated vasculitis.
How they make money
Q32 Bio Inc. is a clinical-stage biotechnology company that does not currently generate revenue from product sales. Its business model relies on raising capital through equity offerings and potential future licensing or collaboration agreements to fund the research and development of its pipeline of biologic therapies for autoimmune and inflammatory diseases.
Products & services
The company is developing a pipeline of biologic candidates, including bempikibart (ADX-914), an anti-IL-7R antibody, and ADX-097, a complement-targeted therapeutic, aimed at treating various autoimmune and inflammatory conditions.
Brands & revenue mix
No separate brand or brand-level revenue disclosure was confirmed in the reviewed sources. This does not mean the company has no brands.
Product / operating segments
No reconciled product or operating-segment revenue breakdown is available for the current research period. Company-wide revenue remains separate from segment disclosure.
Geographic revenue
No reconciled geographic revenue breakdown was confirmed for the current research period.
Customer types
- Clinical trial participantsSource
Customer concentration
No quantified customer-concentration disclosure is available in the current saved research.
Suppliers, materials & equipment
- Contract Manufacturing Organizations — The company relies on third-party contract manufacturing organizations for the production of its clinical trial materials and drug candidates; specific supplier names are not disclosed.Source
Competitors
- Biopharmaceutical companies — The company competes with various established and emerging biopharmaceutical companies developing therapies for autoimmune and inflammatory diseases.Source
Strengths
- Proprietary pipeline of biologic candidates targeting validated pathways in autoimmune and inflammatory diseases.Source
Sources
Company-specific research
Questions worth answering for QTTB
These questions are generated from this company's current financial and score data so the page adds context instead of treating the headline score as a stand-alone conclusion.
- •Can QTTB maintain its current revenue growth rate and improve the amount of that revenue that turns into earnings and cash?
- •How long can QTTB fund negative free cash flow using its current cash position before it may need more debt or new shares?
- •How is QTTB likely to use its cash advantage: reinvestment, acquisitions, debt reduction, dividends or buybacks?
- •Is QTTB's valuation discount tied to a temporary concern or to a longer-term business risk?
- •What does the current fundamental change risk warning mean for the reliability or interpretation of QTTB's score?
Essential Investment Snapshot
Market Cap
$259.3M
P/E Ratio
2.9
EPS
$2.79
52-Week High
$23.57
52-Week Low
$1.91
Beta
-0.33
Analyst Target
$35.00
Shares Outstanding
29.8M
Total Debt
$5.3M
Dividend
No current dividend
Liquidation Value / Share
$3.56
Momentum & Volatility Signals
Two different market-behavior signals. Momentum measures direction and trend strength. Volatility measures how large and unstable the price moves are, regardless of direction.
Weakening momentum
High movement
A high momentum score means price has been trending upward with confirming short- and medium-term strength. A low score means downward or weakening momentum.
A high volatility score means larger, less stable price swings. It can happen while a stock is rising or falling, so high volatility is not automatically bullish or bearish.
Important: the volatility score above is based on realized price volatility. Implied volatility (IV) comes from options prices and represents the market's expected future movement. Wall Street Score will keep IV separate and will only display it when a verified options-chain feed is available.
Community Sentiment
0 active · 0 total callsNo personal call yet on QTTB.
Potential upside factors
- +Growth opportunities may come from revenue expansion, margin improvement, new products, market-share gains, and stronger cash flow.
- +Proprietary pipeline of biologic candidates targeting validated pathways in autoimmune and inflammatory diseases.
Potential downside factors
- −Key risks may include competition, margin pressure, debt levels, valuation risk, and changes in demand within the Biotechnology industry.
- −History of operating losses and expectation of continued losses for the foreseeable future.
- −Dependence on the success of clinical-stage product candidates which may fail in clinical trials.
- −Diluted weighted-average shares increased 15.6% year over year.
These research factors come from saved company research and financial data, not community votes. They are starting points to verify against filings, not buy or sell recommendations.
Create a free account to make a call.
Scores
Click any score for full breakdownWas this stock page easy to understand?
One click helps us improve the research experience. This is not tied to an investment decision.
Score Changes
Score changes will appear once more historical records are available.
Price vs. Value
Review model assumptionsThis model estimate is more than three times the share price.
This is a formula-based estimate, not a verified fair value or price target. Check the earnings and growth assumptions.
Stored EPS: $2.79 · Growth assumption: 0.0% · Earnings multiplier: 0.0×.
Current Price
$8.71
Model Intrinsic Value
$107.42
Difference
−$98.71
-91.9% vs IV
Margin of Safety
91.9%
Financial Charts
Revenue
Additional Metrics
Operating Cash Flow
Total Debt
Total Assets
Net Margin %
Large reported revenue change: +908.0%
Revenue changed sharply from 2023 to 2025. This can reflect a real business change, acquisition, divestiture, discontinued operations, restatement, or reporting-basis change. Compare the underlying filing before treating it as normal growth or decline.
TTM may combine quarters from before and after the event, so its trend can also be distorted.
Free includes 3 annual periods plus available TTM; Premium includes up to 10 annual periods. History depends on available company filings. Swipe the table horizontally to see older periods. A dash means unavailable, not zero.
| Line Item | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $53.7M | $53.7M | $0.00 | -$6.7M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Cost of Revenue | $85K | $0.00 | $0.00 | $0.00 | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Gross Profit | $53.7M | $53.7M | $0.00 | -$6.7M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Research & Development | $14.3M | $19.2M | $48.1M | $31.7M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| SG&A Expenses | $17.9M | $17.7M | $18.0M | $9.9M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Operating Expenses | $32.2M | $36.8M | $66.1M | $41.6M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| EBITDA | $36.0M | $31.3M | -$44.5M | -$47.8M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Operating Income | $21.5M | $16.9M | -$66.1M | -$48.3M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Interest Expense | $1.3M | $1.1M | $1.1M | $0.00 | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Income Before Tax | $33.8M | $29.8M | -$47.7M | -$53.4M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Income Tax Expense | $0.00 | $0.00 | $21K | $318K | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Net Income | $33.8M | $29.8M | -$47.7M | -$53.7M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Basic EPS | $3.12 | $2.42 | $-5.12 | $-4.51 | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Basic Shares | 14.10M | 12.30M | 9.32M | 11.93M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Diluted Shares | 14.10M | 12.31M | 9.66M | 11.93M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
Earnings Summary
Revenue
$0
Estimate unavailable.
Revenue Beat/Miss
Not available (no estimate stored)
EPS
-$0.44
Estimate unavailable.
EPS Beat/Miss
Not available (no estimate stored)
Debt Change
-71.7%
Cash Change
+93.8%
Margin Change
Not available
Debt and cash show percentage changes versus the comparison period; margin shows the change in percentage points (pp). These are company-wide changes, not per-share amounts.
Financial Changes Since Prior Period
What Improved
- Cash position grew
- Debt reduced
Potential Score Impact
Positive indicators included cash levels, debt levels. Pressure indicators included EPS growth. These factors may support or pressure the Revenue, Management, Financial, and Debt categories; this summary does not claim that the stored scores changed.
Stored Earnings Analysis
EPS declined 43.6%. Cash increased 93.8%. Total debt declined 71.7%.
Earnings-Call Transcript
Earnings-call transcript analysis is not currently available.
These results may influence future scores when the next evaluation is completed.
Insider Activity
Guru / Smart Money
Guru Score
Smart Money
Number of Gurus
Total Guru Value
Avg Portfolio Weight
Largest Holder
Largest Holder %
New Positions
Increased Positions
Reduced Positions
Exited Positions
Net Guru Sentiment
Short Interest
Dividend History
Dividend data is not available yet. Missing data does not mean this company pays no dividend.
Conservative Projected Values
3 Years
$———.——
5 Years
$———.——
10 Years
$———.——
Conservative Projection Rate
——%
Conservative Projected Values — price projections derived from actual 10-year adjusted historical returns, conservatively adjusted and capped at 8% annually. These are distinct from the Outperformance Model Score and WallStreetScore.
Conservative Projected Values
Premium unlocks the 3-year, 5-year, and 10-year conservative projected values with full calculation breakdowns based on actual historical returns.
Start 7-Day Free TrialHistorical Outperformance Record
Premium includes stored forecasts and any available evaluated results. Completed results, win rates and calibrated probabilities are shown only when supported records exist; access does not create historical outcomes.
Start 7-Day Free TrialHistorical Trends
4 historical recordsHistorical Score Chart
3 of 4 records shownWall Street Score
Debt Score
Revenue Score
Asset Score
Capital Score
Management Score
Moat Score
Valuation Score
Buffett Score
Intrinsic Value
Value Reference
Margin of Safety %
Related Companies
BiotechnologyNews
Head to Head Contrast: Q32 Bio (NASDAQ:QTTB) & Applied Therapeutics (NASDAQ:APLT)
Q32 Bio Presents Results from Part B of the SIGNAL-AA Clinical Trial of Bempikibart in Alopecia Areata in a Late-Breaker at the European Academy of Dermatology and Venereology Congress 2026
Q32 Bio: Durable Hair Regrowth Remains The Goal
Q32 Bio Announces Upcoming Late-Breaking Presentation of Results from Part B of the SIGNAL-AA Clinical Trial of Bempikibart in Alopecia Areata at the European Academy of Dermatology and Venereology Congress 2026
Rumor Mill · QTTB
Corporate developments & opportunities
No reviewed developments match this filter.
Evidence credibility is not a forecast of stock performance. Rumor Mill is separate from the WSS score.
Related Stock Research
Continue researching this company with related Wall Street Score rankings and investing guides.
Score Alerts
Premium unlocks alerts when a score rises, falls, or reaches your target price.
Start 7-Day Free TrialPortfolio Score
Premium unlocks portfolio scoring, strongest and weakest holdings, and overall margin of safety.
Start 7-Day Free Trial